Episode

Author Interview: Ibrutinib for newly diagnosed primary CNS lymphoma

Podcast
Neuro-Oncology: The Podcast
Published
Mar 2, 2026
Duration seconds
1247
Processing state
not_requested
Canonical source
https://soc-neuro-onc.libsyn.com/author-interview-ibrutinib-for-newly-diagnosed-primary-cns-lymphoma
Audio
https://traffic.libsyn.com/secure/soc-neuro-onc/nop-118-authorinterview.mp3?dest-id=2339594
JSON
/v1/public/podcasts/neuro-oncology-the-podcast-1565653/episodes/author-interview-ibrutinib-for-newly-diagnosed-primary-cns-lymphoma
Markdown
/podcast/neuro-oncology-the-podcast-1565653/author-interview-ibrutinib-for-newly-diagnosed-primary-cns-lymphoma.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/neuro-oncology-the-podcast-1565653/episodes/author-interview-ibrutinib-for-newly-diagnosed-primary-cns-lymphoma/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/neuro-oncology-the-podcast-1565653/author-interview-ibrutinib-for-newly-diagnosed-primary-cns-lymphoma.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Dr. Maya Graham interviews Dr. Lauren Schaff on her manuscript entitled "Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)," published in Neuro-Oncology in January 2026.